CURASEPT ADS | DNA 712 GEL TOOTHPASTE

Chlorhexidine digluconate 0.12% with ADS, DNA

Format: 75 ml

Prolonged anti-plaque action.
Maintains the whiteness of your teeth.

It is recommended to be used in combination with Curasept 212 mouthwash.

Use:

Supplement to mouthwash in prolonged anti-plaque treatment, in gum irritation.
Use two or three times a day up to four months.

The combination with the corresponding mouthwash and toothbrush completes the treatment.

In some countries, this product is available in the ADS version. To check availability in your country, please contact the relevant distributor.

Related products

CURASEPT ADS | DNA 212 MOUTHWASH

CURASEPT ADS 350 PERIODONTAL GEL

Curasept Softline soft 015 toothbrush and blister

CURASEPT SOFTLINE SOFT TOOTHBRUSH 015

shock action mousse home and pack Curasept Biosmalto Caries Abrasion Erosion mint and strawberry flavors

CURASEPT SOFTLINE TOOTHBRUSH EXTRA SOFT 012

Accessibility Adjustments

Select your accessibility profile

Vision Impaired Mode

Enhances website's visuals

Seizure Safe Profile

Clear flashes & reduces color

ADHD Friendly Mode

Focused browsing, distraction-free

Blindness Mode

Reduces distractions, improves focus

Epilepsy Safe Mode

Dims colors and stops blinking

Content

Colors

Orientation

Quality Policy

The Quality for CURASEPT S.p.A. is an essential condition to put itself successfully on the market, considering its characteristics and evolution.

The development of the Company and its profit are insured by the continuous search for quality towards excellence through the continuous improvement of its processes and the search for partners with quality systems adapted to our standards.

The Company aims to increase the customer satisfaction through the application of its Quality Management System, including the processes to improve the system and to ensure the compliance with the customer and applicable regulatory requirements.

For this purpose, the Company performs specific risks and opportunities assessment activities, connected to the context, stakeholders and related objectives, in order to identify the areas of system improvements and to define the appropriate actions for the risk control and mitigation and strengthening of its Quality System.

The starting point for the implementation of this policy is the pursuit of the following objectives:

Define and implement a Quality Management System according to 9001:2015+A1:2024 e UNI CEI EN ISO 13485:2021 regulation, as Manufacturer of Medical Devices;
Define and implement a system of procedures and operating instructions in harmony with the Directive 93/42/CEE, the Regulation (UE) 2017/745 and the Regulation (UE) 2023/607 for the applicable parts and subsequent changes and integrations, which satisfy the essential requirements set out in Annex I;
Define and implement a system of procedures in harmony with the Directive 2010/84, the Regulation 1235/2010, the Implementation Regulation n. 520/2012 and in accordance with the objectives of “module I – “Good Vigilance Practices” (GVP);
Establish and formalize the business organizational structure with the subdivision into areas of competences;
Clarify roles and responsibilities of business functions;
Define strategies and objectives and assign human and material resources for their achievement;
Define accurately business processes and related performance factors;
Ensure compliance with qualitative, quantitative and temporal requirements;
Constantly monitor the level of adequacy of the system with reference to regulations and laws;
Promote initiatives in order to improve the process of motivational and professional growth of human resources, considered as critical resources for future business developments;
Ensure the commitment to the satisfaction of requirements and the maintenance of effectiveness of the Quality Management System.

These objectives can be realized thanks to the involvement of the whole Company personnel.

In particular, the Managers of each Function provide their contribution so that the suggested improvements can be proposed to the General Direction, so that the Quality Policy can be a priority element in the choice of business qualitative and organizational strategies.

The involvement of the whole personnel in the improvement of internal and external processes should be aimed at reducing non-compliance and internal and external costs of non-quality; for this reason all employees should feel themselves committed in pursuing this policy.

Training courses, for all business levels, are promoted and planned by the General Direction in order to keep the personnel constantly up to date on the improvements performed for the processes.

The Quality Manual, which is distributed via the SistemaQualità to all process managers and the General Director, should represent a work tool for all Managers and their personnel for the implementation of the Quality Policy.

April 2025

General Direction

CURASEPT ADS | DNA 712 GEL TOOTHPASTE

Use:

Related products

Curasept S.p.A.

FOLLOW US ON

COMPANY

NEEDS

PRODUCTS

BRANDS

Accessibility Adjustments

Bigger Text

Cursor

Line Height

Letter Spacing

Readable Font

Dyslexic Font

Align Text

Text Magnifier

Highlight Links

Invert Colors

Brightness

Contrast

Grayscale

Saturation

Reading Line

Keyboard Navigation

Highlight Titles

Reading Mask

Hide Images

Highlight Al

Read Page

Mute Sounds

Stop Animations

Vuoi accedere ai contenuti Extra? Registrati o fai Login per accedere ai contenuti a te dedicati: articoli, video ,schede… e tanto altro!

CURASEPT ADS | DNA 712 GEL TOOTHPASTE

Use:

Related products

Curasept S.p.A.

FOLLOW US ON

COMPANY

NEEDS

PRODUCTS

BRANDS

Vuoi accedere ai contenuti Extra? Registrati o fai Login per accedere ai contenuti a te dedicati: articoli, video ,schede… e tanto altro!

THE FIRST NON-STAINING CHLORHEXIDINE

Quality Policy